Literature DB >> 27392183

The science of vaccine adjuvants: advances in TLR4 ligand adjuvants.

Steven G Reed1, Fan-Chi Hsu2, Darrick Carter2, Mark T Orr2.   

Abstract

TLR ligands are used in modern vaccine adjuvants, TLR4 ligand-based adjuvants are the most advanced in commercial vaccines. Increased understanding of TLR4 receptor-ligand interactions enables chemical synthesis and modification of new leads and our understanding of the biological/immunological mechanisms of combination adjuvants enables formulation of potent and safe vaccine compositions. Characterization of non-glycolipid TLR4 ligands provided new mechanistic information that could lead to new formulations. This review discusses advances in TLR4 agonist design-both glycolipid and non-glycolipid based TLR4 ligands-as well as CD14 activation as options to activate or synergize with TLR4 signaling. Finally, we review the molecular and cellular mechanisms that are elicited by formulated TLR4 targeted combination adjuvants during the initiation of innate immune responses leading to quality adaptive responses.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27392183     DOI: 10.1016/j.coi.2016.06.007

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  24 in total

1.  A new multi-epitope peptide vaccine induces immune responses and protection against Leishmania infantum in BALB/c mice.

Authors:  Bahareh Vakili; Navid Nezafat; Bijan Zare; Nasrollah Erfani; Maryam Akbari; Younes Ghasemi; Mohammad Reza Rahbar; Gholam Reza Hatam
Journal:  Med Microbiol Immunol       Date:  2019-11-06       Impact factor: 3.402

Review 2.  Adjuvants: tailoring humoral immune responses.

Authors:  M Juliana McElrath
Journal:  Curr Opin HIV AIDS       Date:  2017-05       Impact factor: 4.283

3.  Pentaerythritol-based lipid A bolsters the antitumor efficacy of a polyanhydride particle-based cancer vaccine.

Authors:  Emad I Wafa; Sean M Geary; Kathleen A Ross; Jonathan T Goodman; Balaji Narasimhan; Aliasger K Salem
Journal:  Nanomedicine       Date:  2019-07-15       Impact factor: 5.307

4.  Metabolic engineering of Escherichia coli to produce a monophosphoryl lipid A adjuvant.

Authors:  Yuhyun Ji; Jinsu An; Dohyeon Hwang; Da Hui Ha; Sang Min Lim; Chankyu Lee; Jinshi Zhao; Hyun Kyu Song; Eun Gyeong Yang; Pei Zhou; Hak Suk Chung
Journal:  Metab Eng       Date:  2019-11-28       Impact factor: 9.783

Review 5.  Toll-Like Receptors: Regulators of the Immune Response in the Human Gut.

Authors:  Hubert Hug; M Hasan Mohajeri; Giorgio La Fata
Journal:  Nutrients       Date:  2018-02-13       Impact factor: 5.717

6.  Control of Heterologous Simian Immunodeficiency Virus SIVsmE660 Infection by DNA and Protein Coimmunization Regimens Combined with Different Toll-Like-Receptor-4-Based Adjuvants in Macaques.

Authors:  Shakti Singh; Eric G Ramírez-Salazar; Rami Doueiri; Antonio Valentin; Margherita Rosati; Xintao Hu; Brandon F Keele; Xiaoying Shen; Georgia D Tomaras; Guido Ferrari; Celia LaBranche; David C Montefiori; Jishnu Das; Galit Alter; Hung V Trinh; Christopher Hamlin; Mangala Rao; Frances Dayton; Jenifer Bear; Bhabadeb Chowdhury; Candido Alicea; Jeffrey D Lifson; Kate E Broderick; Niranjan Y Sardesai; Sandra J Sivananthan; Christopher B Fox; Steven G Reed; David J Venzon; Vanessa M Hirsch; George N Pavlakis; Barbara K Felber
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

7.  A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity.

Authors:  Fumi Sato-Kaneko; Shiyin Yao; Fitzgerald S Lao; Jonathan Shpigelman; Karen Messer; Minya Pu; Nikunj M Shukla; Howard B Cottam; Michael Chan; Paul J Chu; David Burkhart; Roman Schoener; Takaji Matsutani; Dennis A Carson; Maripat Corr; Tomoko Hayashi
Journal:  Front Immunol       Date:  2020-06-19       Impact factor: 7.561

8.  The differences in immunoadjuvant mechanisms of TLR3 and TLR4 agonists on the level of antigen-presenting cells during immunization with recombinant adenovirus vector.

Authors:  Ekaterina Lebedeva; Alexander Bagaev; Alexey Pichugin; Marina Chulkina; Andrei Lysenko; Irina Tutykhina; Maxim Shmarov; Denis Logunov; Boris Naroditsky; Ravshan Ataullakhanov
Journal:  BMC Immunol       Date:  2018-07-28       Impact factor: 3.615

Review 9.  Biodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes Targeting.

Authors:  Alice Gutjahr; Capucine Phelip; Anne-Line Coolen; Claire Monge; Anne-Sophie Boisgard; Stéphane Paul; Bernard Verrier
Journal:  Vaccines (Basel)       Date:  2016-10-12

Review 10.  Dendritic Cells in the Cross Hair for the Generation of Tailored Vaccines.

Authors:  Laura Gornati; Ivan Zanoni; Francesca Granucci
Journal:  Front Immunol       Date:  2018-06-27       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.